MENU
BBP
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

BBP stock forecast, quote, news & analysis

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
a Summary for BBP with price predictions
Nov 10, 2026

BBP in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 06, 2026

BBP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 37 of 42 cases where BBP's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +3.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where BBP advanced for three days, in 278 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 68 of 75 cases where BBP's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BBP as a result. In 72 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.

The Moving Average Convergence Divergence Histogram (MACD) for BBP turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 43 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.

BBP moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for BBP crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

The Aroon Indicator for BBP entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Sarepta Therapeutics (NASDAQ:SRPT).

Industry description

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ("FDA") for marketing.

Market Cap

The average market capitalization across the Virtus Biotech ETF (BBP) ETF is 20.36B. The market cap for tickers in the group ranges from 424.73M to 248.92B. AMGN holds the highest valuation in this group at 248.92B. The lowest valued company is PHAT at 424.73M.

High and low price notable news

The average weekly price growth across all stocks in the Virtus Biotech ETF (BBP) ETF was 54%. For the same ETF, the average monthly price growth was 94%, and the average quarterly price growth was 404%. XERS experienced the highest price growth at 53%, while SNDX experienced the biggest fall at -34%.

Volume

The average weekly volume growth across all stocks in the Virtus Biotech ETF (BBP) ETF was 10%. For the same stocks of the ETF, the average monthly volume growth was 5% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 52
Price Growth Rating: 49
SMR Rating: 73
Profit Risk Rating: 66
Seasonality Score: 5 (-100 ... +100)